William Blair Predicts Nkarta’s Q2 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Equities research analysts at William Blair cut their Q2 2025 EPS estimates for shares of Nkarta in a research report issued to clients and investors on Thursday, May 15th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.50) per share for the quarter, down from their previous estimate of ($0.45). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta’s Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($1.95) EPS.

A number of other brokerages have also weighed in on NKTX. Needham & Company LLC reduced their price target on Nkarta from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Nkarta in a research report on Thursday, March 27th. Finally, Stifel Nicolaus reduced their target price on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $14.67.

Nkarta Stock Performance

Shares of NASDAQ NKTX opened at $1.80 on Monday. The firm has a market cap of $127.72 million, a P/E ratio of -0.96 and a beta of 0.81. Nkarta has a 1 year low of $1.31 and a 1 year high of $8.23. The firm’s 50 day moving average price is $1.79 and its 200 day moving average price is $2.18.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.01.

Institutional Trading of Nkarta

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Jefferies Financial Group Inc. boosted its holdings in Nkarta by 901.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock valued at $6,236,000 after acquiring an additional 2,254,219 shares during the last quarter. Tang Capital Management LLC raised its holdings in shares of Nkarta by 252.9% in the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock worth $5,711,000 after purchasing an additional 1,643,719 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Nkarta by 138.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock worth $6,319,000 after purchasing an additional 1,474,560 shares during the period. Jane Street Group LLC lifted its stake in shares of Nkarta by 118.7% in the 1st quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after purchasing an additional 852,559 shares in the last quarter. Finally, Monaco Asset Management SAM purchased a new stake in shares of Nkarta during the 1st quarter worth about $1,496,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.